CBD and endometriosis: what the research really says in 2026

Endometriosis is a chronic inflammatory disease in which tissue similar to the endometrium develops outside the uterus, causing pelvic pain and fatigue. Conventional painkillers are not always enough, and surgery does not settle everything. The endocannabinoid system, a network of receptors involved in pain and inflammation, is present in reproductive tissues, which makes cannabidiol biologically plausible as a line of enquiry. A 2024 review published in Trends in Pharmacological Sciences sets out this rationale and considers it a serious target to explore (Mistry et al., 2024). Plausibility, however, is not proof of efficacy.

The preclinical data, from cell and animal models, suggest an anti-inflammatory and potentially anti-lesional effect of cannabinoids. In these models they reduce inflammation and, in some experiments, decrease lesion size (Mistry et al., 2024). What shrinks a lesion in a mouse does not automatically translate into a benefit in women: doses and metabolism differ. Animal data serve to formulate hypotheses and justify human trials, not to recommend use.

The DREAMLAND trial is evaluating a CBD oil for pelvic pain in women after endometriosis surgery. Many participants experienced clinically significant pain reductions, with an improvement in the interference of pain with sleep and daily activities. These results must nevertheless be read with nuance: a single trial, however well conducted, does not constitute definitive proof. They need to be confirmed in larger populations before any clinical recommendation.

Several trials are under way in the United States, Brazil, the United Kingdom and Australia, most of them pilot studies designed to check tolerability, safety and dosing. In the United Kingdom, the ENDO-CAN1 trial run by the University of Edinburgh is seeking to establish the dose of a candidate medicine, MRX-1. To reach a genuine conclusion on efficacy, a large multinational randomised trial comparing CBD with a placebo in many participants will be needed, with harmonised formulations and follow-up durations.

Not all sources of information carry the same weight: an animal model, a pilot trial and a self-reported survey do not have the same scientific standing. Preclinical data remain weak and cannot be transposed directly to humans. The DREAMLAND trial provides a moderate level of evidence, still to be confirmed. Usage surveys, in which patients report reducing their use of painkillers with cannabis, are useful but uncontrolled and exposed to selection bias: these are self-reported data, not efficacy demonstrated by a placebo-controlled trial.

The honest answer is: not without medical advice. CBD is not a medicine and replaces neither a diagnosis, nor follow-up, nor prescribed treatments (Inserm). If you are considering CBD as a comfort supplement, talk to your doctor or gynaecologist first, especially if you are on treatment; never stop a prescription on your own initiative; and favour traceable products with a certificate of analysis. Our article on CBD's interactions with the liver sets out the precautions to know before combining it with a treatment.

Does CBD cure endometriosis?

No. No data allow it to be claimed that CBD cures endometriosis or makes its lesions regress in women. Research focuses mainly on pain relief, with results that are still preliminary.

Does CBD reduce pelvic pain?

The data suggest a possible effect, not a proven one. The DREAMLAND trial reports clinically significant reductions after surgery, but a single trial still has to be confirmed by larger studies.

How many women are affected by endometriosis?

Around one woman in ten of childbearing age, according to Inserm. This high prevalence, often diagnosed late, explains the growing research interest in new avenues.

Does CBD carry risks with other treatments?

Yes, it can interact with certain medicines metabolised by the liver. It is essential to discuss this with your doctor before any use, especially if you are on treatment for endometriosis.